GlassScriptPhysician profile
Emily Anne Daniel
NPI 1639878853
$829.71
in general payments reported to CMS, 2019-2025
21 companies · $173 in 2025
The $173 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $657 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $87.14 | 2023 | |
| Novo Nordisk INC | $84.83 | 2025 | Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $84.76 | 2023 | Gammagard |
| Otsuka America Pharmaceutical, INC. | $65.03 | 2023 | Abilify Maintena, Rexulti |
| Neurocrine Biosciences, INC. | $60.90 | 2023 | Ongentys, Ingrezza |
| Jazz Pharmaceuticals INC. | $57.72 | 2023 | |
| Abbvie INC. | $51.00 | 2023 | |
| Kyowa Kirin, INC. | $41.86 | 2023 | Nourianz |
| Argenx US, INC. | $38.06 | 2023 | Vyvgart |
| Biogen, INC. | $34.59 | 2023 | Tysabri, Vumerity |
| Antares Pharma, INC. | $29.93 | 2025 | Xyosted |
| Exact Sciences Corporation | $26.26 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $23.64 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $21.02 | 2025 | Farxiga |
| Gilead Sciences, INC. | $20.28 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $20.02 | 2023 | Horizant |
| Merz Pharmaceuticals, LLC | $19.84 | 2023 | Xeomin |
| Amgen INC. | $16.89 | 2025 | Repatha |
| Harmony Biosciences LLC | $16.45 | 2023 | Wakix |
| Eisai INC. | $15.50 | 2023 | |
| Lilly USA, LLC | $13.99 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.